Ferron Par Pharmaceuticals was established to augment the growth of Dexa Group, by providing enhanced production, development, and marketing capabilities. Within four years of inception, its rapid growth saw it listed among the 20 largest pharmaceutical operations in Indonesia.1
Ferron collaborates with partners across the world, and harnesses an extensive API-sourcing network as well as over 50 years of experience from the larger Dexa Group. Its facility has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA, the United Kingdom), Therapeutic Goods Administration (TGA, Australia), and the Federal Institute for Drugs and Medical Devices (BfArM, Germany).
Ferron has leveraged these assets to build a strong presence in Europe.
1IHPA+IPA 2005; IMS Audit 2005
The name Ferron was inspired by the Latin ferreus (“made of iron”), as a reminder of the inner strength of the company’s values. The three sides of Ferron’s triangular logo represent its three core priorities: care, quality, and innovation.
By leveraging its extensive API sourcing network, Ferron has successfully implemented highly localized strategies and strengthened access to its medicines across the Southeast region. Ferron started delivering products to the United Kingdom in 2008, just seven years after its inception. Since then, it has continually strengthened its presence in Europe, with most of its products being delivered to clients in the United Kingdom, the Netherlands, and Poland.
Ferron is an established global provider for sterile- and solid-manufacturing of regular, non-beta lactam, non-cephalosporins, and non-oncology products. It has built end-to-end competency spanning co-development, warehouse management, contract manufacturing, and analysis. Its facilities are equipped with state-of-the-art production lines, capable of manufacturing various dosage forms: solids (tablets, coated tablets, capsules), liquids (oral syrups), semi-solids (creams, gels, ointments, suppositories), and sterile solutions (injectables in ampoules, injectables in vials, and eye drops).
|Suspension||Soft-gel capsule||Drops||Dry-powder syrup|
Ferron can work with partners from the beginning of the product life cycle. It regularly helps partners achieve their milestones by creating products in its development facilities. Its numerous existing dossiers help accelerate partner products’ entry into the market. Ferron also helps develop dossiers based on partner requirements.
Ferron utilises its robust infrastructure to deliver manufactured products within budget and time constraints. Its pharmaceutical manufacturing services include aseptic fill finish, non-aseptic fill finish, lyophilization, semi-solid dosage forms and oral dosage forms.
- Aseptic Fill Finish
- Pre-filled Syringes
- Non Aseptic Fill Finish
- Dosage forms
- Sustained Release tablets
- Sustained Release pellets in capsules
- Liquid oral dosage form
- Advanced technology
- Automatic Liquid Inspection Machine
- Robotic Automatic Packaging System
- IoT-based Performance Monitoring System
- Packaging line with serialization system (as per the EU directive on falsified medicines)
Existing, validated methods can be transferred to Ferron. Alternatively, Ferron can also develop product-specific methods in-house. Its full-service laboratories are equipped with a variety of instrumentation to meet testing needs.
- Gas Chromatography with headspace
- Liquid Chromatography – UPLC and HPLC
- Dissolution Tester with automatic sampler
- Measurement of Water Content by Karl Fischer Titration
- pH measurement
- Reconstitution Time
- Subvisible Particulate Matter
- Antimicrobial Effectiveness Test (AET)
- Sterility-closed system with isolator